HPV Testing and PAP Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Primary HPV Testing, PAP Testing, Co-testing), By Application (Cervical cancer, Vaginal Cancer), By End User (Hospital, Diagnostic Centres, Research Institute, Others), and Region

HPV Testing and PAP Testing Market size was valued at US$ 2,567.2 million in 2023 and is poised to grow at a CAGR of 17.1% from 2024-2030. The HPV (Human Papillomavirus) testing is a test done to detect the presence of Papillomavirus in women, which causes cervical cancer or development of genital warts. Factors such as government initiative and funding programs and technological advancement in PAP and HPV test, change in screening guidelines, increasing awareness among the people about the screening program of cervical cancer worldwide and growing ageing population and increasing prevalence of cervical cancer cases are impacting the market growth. According to WHO, cervical cancer is the fourth most common cancer in women globally and around 6,60,000 new cases and 3,50,000 deaths have been seen in 2022. The highest rates of cervical cancer are reported in low income and middle- income countries and is more common in women of age group 25-55 years. This high rate of cervical cancer is due to the lack of access to National HPV vaccination, cervical screening and treatment services, also social and economic determinants are some other factors too.

There are other limiting factors also, for example, in US although free or low-cost cervical cancer screening is available for women aged 21-64 but not all women respond to these invitations. And this is commonly seen in people from particular ethnic and socioeconomic groups, low-income groups, recent immigrants. Significant change in regulatory guidelines for cervical cancer screening which will restraint the growth of this market. As per American Cancer Society, HPV test detect HPV infection and can not detect pre cancer or cancer itself whereas PAP test finds changes in the cells or abnormal cells in the cervix and cannot detect HPV. With more people detecting and treating abnormal cervical cell changes early, the market for cervical cancer prevention is projected to grow in the coming years.

HPV Testing and PAP Testing Market Key Developments:

• In 2022: Roche launched the self-diagnosing and self-sampling method/solution for HPV in CE certification recognised countries.
• In 2021: Hologic, Inc. acquired a privately held European developer and manufacturer of molecular diagnostic assays (DIAGENODE) for approximately $159 million.
• In 2021: QIAGEN N.V launched QIAcube Connect MDx platform for automated samples processing in molecular diagnostic laboratories which will be available in North America, Europe and other markets now.